D. E. Shaw & Co. Inc. Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

D. E. Shaw & Co. Inc. raised its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 100.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 365,544 shares of the company's stock after buying an additional 183,449 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.96% of Tarsus Pharmaceuticals worth $20,240,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TARS. Barclays PLC boosted its position in shares of Tarsus Pharmaceuticals by 345.9% in the third quarter. Barclays PLC now owns 98,663 shares of the company's stock worth $3,246,000 after acquiring an additional 76,538 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in Tarsus Pharmaceuticals by 22.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 22,113 shares of the company's stock worth $1,224,000 after purchasing an additional 4,008 shares during the period. Assenagon Asset Management S.A. raised its stake in Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company's stock worth $63,499,000 after purchasing an additional 5,565 shares during the period. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $53,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $249,000. Hedge funds and other institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $44.87 on Monday. The firm has a market cap of $1.89 billion, a P/E ratio of -11.78 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The stock has a 50-day simple moving average of $48.26 and a 200-day simple moving average of $49.21.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. The firm had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 824,106 shares of the company's stock, valued at $41,205,300. This represents a 0.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Bryan Wahl sold 3,084 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the sale, the general counsel now owns 51,712 shares of the company's stock, valued at $2,591,288.32. This represents a 5.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,542 shares of company stock valued at $1,581,173. Corporate insiders own 8.25% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on TARS. The Goldman Sachs Group increased their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Guggenheim lifted their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Jefferies Financial Group boosted their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Barclays dropped their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $66.33.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.